In addition, in the coming years, oral GLP-1 receptor agonists and injectable formulations that require less-frequent ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

Labels of all GLP-1 receptor agonists now carry a warning about pulmonary aspiration during general anesthesia or deep ...

It is also expected to be cheaper, since it's easier to produce (orforglipron isn't a peptide like other GLP-1 drugs). However, the clock is ticking. Novo Nordisk already has an oral semaglutide ...

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Depending on the medication, the effects can last for a minimum of 24 hours to a few weeks. Examples include dulaglutide, ...

The following is a summary of "Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide ...

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in ... search for a ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...